尤瑞克林联合复方脑肽节苷脂治疗脑梗死分析

茅永翠

启东市第三人民医院 江苏 启东 226200

【摘 要】：目的： 方法： 2021

7 -2022 7 60

NIHSS 结果：

NIHSS 7.25± 2.05 11.35± 2.14

96.67% 80.00% P 0.05 结论：

【关键词】：

Analysis of Urinary Kallidinogenase Combined with Compound Cerebroside in the Treatment of Cerebral Infarction

Yongcui Mao

Qidong Third People's Hospital Jiangsu Qidong 226200

Abstract: Objective: To study the final curative effect of ureklin and compound cerebropeptide in the treatment of patients with cerebral infarction. Methods: From July 2021 to July 2022, 60 patients with cerebral infarction were selected to participate in this two-group controlled experiment. The experimenters grouped and named all the patients according to the principle of randomness and equality. The two groups of patients were treated with different treatment plans, which were compound cerebroside ganglioside alone treatment and uricline combined with compound cerebropeptide ganglioside combined treatment. The two treatment methods were discussed and analyzed according to the NIHSS score and the treatment effective rate presented by the patients before and after treatment. Results: The NIHSS scores of the experimental group and the control group after one month of treatment were 7.25 ± 2.05 and 11.35 ± 2.14, and the experimental group showed obvious advantages. In terms of the total effective rate of treatment, the total effective rate of the experimental group was 96.67%, which was significantly higher than the 80.00% effective rate of the control group. The above data comparisons all reached the standard of P less than 0.05. Conclusion: In the treatment process of patients with cerebral infarction, the combined treatment of uricrine and compound cerebroside ganglioside can effectively improve the therapeutic effect of patients and promote the recovery process of patients.

Keywords: Eureckering; Compound brain peptide gangliosides; Cerebral infarction; Efficacy analysis

1 资料与方法

1.1

2021 7 ~2022 7

60

68.3± 2.9

[1]

MRI CT

[2]

1.2

[8]

10ml   250ml   5% [3]   CT

MRI   [9]

0.15U

250ml [4]

1.3

2   1   NIHSS

NIHSS

NIHSS   90%   NIHSS

30%

1.4

SPSS 21.0

t   [10]

2 结果

20   66.67%

9   30.00%   1   3.33%

96.67%   17 56.67%

7   23.33%   6   20.00%

80.00%   P<0.05

NIHSS $\bar{x}\pm s$

		2	1
	18.45± 3.15	14.76± 2.43a	11.35± 2.14a
	18.52± 3.06	12.26± 2.16ab	7.25± 2.05ab

aP<0.05   bP<0.05

3 讨论

[5]

[6- 7]   PH

c

3.33%

NIHSS

NIHSS

参考文献：

[1]　　　　 ,　　 ,　　 .
　　　　　　　　　　　　[J].　　　　　　　　　 ,
2022,37(6):1253-1258.

[2]　　　 ,　　　 ,　　　 .
　　　　　　　　　　　　　　　 S100β 　 NSE
8-iso-PGF2α 　 MDA 　　　　[J].　　　　　 , 2021,44
(5):1060-1065.

[3]　　　 ,　　 .
　　　　[J].　　　　　 ,2021,18(2):73.

[4]　　　 ,　　 ,　　　 , .
　　　　　　　　　　　　　　　　[J].
　　 ,2020,40(11):2258-2261.

[5]　　　 ,　　 ,　　　 , .
　　　　　　　　　　 Lp-PLA2 hs-CRP NSE
　　 [J].　　　 ,2020,26(3):393-397.

[6]　　 .　　　　　　　　　　　[J].
　 ,2022,23(1):137-138.

[7]　　　 ,　　 ,　　　 .
　　　　　　　　　　　　　　　　[J].
　　 ,2022,44(1):23-26.

[8]　　 .
　　　　　　 CXCL16 　 CD40L 　　 [J].
　 ,2022,20(1):27-30.

[9]　　　 ,　　 ,　 .
　　　　　 [J].　　 ,2022,7(9):74-77.

[10]　　 .
　　　　 [J].　　　　 ,2022,19(2):51-53.